Häussler D, Sommer J U, Nastev A, Aderhold C, Wenzel A, Kramer B, Stuck B A, Birk R
Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany.
Eur Arch Otorhinolaryngol. 2018 Jun;275(6):1483-1490. doi: 10.1007/s00405-018-4979-3. Epub 2018 Apr 19.
MP 29-02, which contains fluticasone propionate and azelastine hydrochloride, is used as a topical nasal application for the treatment of seasonal and perennial allergic rhinitis. Although a multitude of data is available on the clinical symptom reduction and treatment safety of MP 29-02, the effect of MP 29-02 on ciliary beat frequency (CBF) has not been evaluated thus far.
MP 29-02-containing solution was applied at concentrations of 2.5, 5, 10, and 20% to 14 healthy subjects, and nasal ciliated epithelial cells were then visualized using a phase-contrast microscope. CBF was measured after the application of MP 29-02. For a comparison, fluticasone propionate was used. CBF measurements were then performed for 15 min at 22 °C. Ringer's solution was applied as a negative control.
MP 29-02 significantly reduced CBF at all the tested concentrations compared with that of the control group within the observation time. At a 2.5% concentration, MP 29-02 significantly reduced CBF from 6.81 Hz (SD ± 1.35 Hz) at baseline to 4.88 Hz (SD ± 1.52 Hz, p < 0.001) after 15 min. In contrast, for fluticasone propionate, a significant reduction was observed only with the 20% concentration after 5, 10, and 15 min.
MP 29-09 significantly reduced CB, with an almost linear relationship between the MP 29-09 concentration and reduction in CBF. For fluticasone propionate, a significant reduction of CBF was observed only at the highest analyzed concentration. The findings have implications for the long-term use of the MP 29-02. Yet, further clinical studies are needed to confirm these results in vivo, especially in patients with seasonal or perennial allergic rhinits.
MP 29-02含有丙酸氟替卡松和盐酸氮卓斯汀,用作局部鼻腔用药治疗季节性和常年性过敏性鼻炎。尽管已有大量关于MP 29-02临床症状减轻和治疗安全性的数据,但MP 29-02对纤毛摆动频率(CBF)的影响迄今尚未评估。
将含MP 29-02的溶液以2.5%、5%、10%和20%的浓度应用于14名健康受试者,然后用相差显微镜观察鼻纤毛上皮细胞。在应用MP 29-02后测量CBF。作为对照,使用丙酸氟替卡松。然后在22℃下进行15分钟的CBF测量。应用林格氏液作为阴性对照。
在观察时间内,与对照组相比,MP 29-02在所有测试浓度下均显著降低CBF。在2.5%浓度下,MP 29-02在15分钟后使CBF从基线时的6.81Hz(标准差±1.35Hz)显著降低至4.88Hz(标准差±1.52Hz,p<0.001)。相比之下,对于丙酸氟替卡松,仅在5、10和15分钟后,20%浓度时观察到显著降低。
MP 29-09显著降低CB,且MP 29-09浓度与CBF降低之间几乎呈线性关系。对于丙酸氟替卡松,仅在分析的最高浓度下观察到CBF显著降低。这些发现对MP 29-02的长期使用有影响。然而,需要进一步的临床研究在体内证实这些结果,尤其是在季节性或常年性过敏性鼻炎患者中。